🧠 This Week in Immunology: CBD for UVA, CAR-T for Autoimmune, and Real-World Gout Trials
Stay up to date with the latest immunology developments—spanning first-in-human studies, regulatory milestones, and global therapeutic innovations:
💉 ANI Pharmaceuticals kicks off a Phase 4 trial of Cortrophin Gel for acute gout—led by Dr. Hyon Choi to inform real-world dosing strategies.
🌍 Sandoz launches the first ustekinumab biosimilar autoinjector in Europe—starting in Spain with a broader EU rollout ahead.
🧴 FDA approves Arcutis’ ZORYVE Foam for scalp and body psoriasis—offering rapid itch relief for patients 12 and older.
🔬 Triveni Bio initiates its first-in-human trial of TRIV-509, a KLK-targeting therapy aiming to restore the skin barrier in atopic dermatitis.
🌞 MINO Labs publishes landmark data from the first human trial of a CBD cream—demonstrating DNA protection from UVA damage.
🖥️ MedX expands its teledermatology network in Italy—enhancing early skin cancer detection through pharmacy-based lesion assessment.
🧬 AbelZeta presents promising early results for its dual-target CAR-T therapy, C-CAR168—showing immune reset in lupus nephritis and MS, with patients achieving remission off immunosuppressants.
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on the latest in immunology and autoimmune diseases
#Immunology #CAR_Therapy #PsoriasisTreatment #CBDResearch #AutoimmuneUpdates #GoutTreatment #DermatologyInnovation #ClinicalTrials #LucidQuest #ImmunologyNews #Teledermatology #MedicalBreakthroughs